Skip to main content

Cow's Milk Allergy

1
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

DBV Technologies
DBV TechnologiesFrance - Châtillon
1 program
1
DBV1605Phase 21 trial
Active Trials
NCT04492683Unknown230Est. Mar 2024
Abbott
AbbottABBOTT PARK, IL
2 programs
Experimental Extensively Hydrolyzed FormulaN/A1 trial
Experimental Extensively Hydrolyzed FormulaN/A1 trial
Active Trials
NCT04910373Terminated1Est. Feb 2022
NCT06456541Recruiting61Est. Jan 2029
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Amino Acid formulaN/A1 trial
Active Trials
NCT01584245Terminated32Est. Jul 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
DBV TechnologiesDBV1605
AbbottExperimental Extensively Hydrolyzed Formula
AbbottExperimental Extensively Hydrolyzed Formula
Johnson & JohnsonAmino Acid formula

Clinical Trials (4)

Total enrollment: 324 patients across 4 trials

NCT04492683DBV TechnologiesDBV1605

Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children

Start: Aug 2020Est. completion: Mar 2024230 patients
Phase 2Unknown
NCT06456541AbbottExperimental Extensively Hydrolyzed Formula

Infant Formula in Infants and Children With Cow's Milk Allergy

Start: Oct 2024Est. completion: Jan 202961 patients
N/ARecruiting
NCT04910373AbbottExperimental Extensively Hydrolyzed Formula

Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy

Start: Jan 2022Est. completion: Feb 20221 patients
N/ATerminated
NCT01584245Johnson & JohnsonAmino Acid formula

Evaluation of the Efficacy of an Amino Acid Based Formula in Infants

Start: Feb 2012Est. completion: Jul 201432 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 324 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.